

INOVIO PHARMACEUTICALS, INC.  
Form 8-K  
May 17, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report**

**(Date of earliest event reported)**

**May 13, 2016**

**INOVIO PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction)**

**001-14888**  
**(Commission)**

**33-0969592**  
**(I.R.S. Employer)**



**Item 1.01. Entry into a Material Definitive Agreement.**

As reported in Item 5.07 of this Form 8-K current report, the stockholders of the Company approved the Company's 2016 Omnibus Incentive Plan at the Company's 2016 Annual Meeting of Stockholders held on May 13, 2016. A description of the Company's 2016 Omnibus Incentive Plan is included in the Company's proxy statement for its 2016 Annual Meeting of Stockholders, filed with the Securities and Exchange Commission on March 25, 2016, which description is incorporated by reference into this Form 8-K as though fully set forth herein.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

Inovio Pharmaceuticals, Inc. (the Company) held its 2016 Annual Meeting of Stockholders on May 13, 2016. The following are the voting results for each matter voted upon:

Proposal 1: The election of the following nominees as directors of the Company to serve until the Company's 2017 Annual Meeting of Stockholders and until their successors are elected.

Name of Director Nominee	Votes For	Votes Withheld	Broker Non-Votes
Avtar S. Dhillon	19,721,659	4,704,564	29,257,770
J. Joseph Kim	24,044,525	381,698	29,257,770
Simon X. Benito	22,179,757	2,246,466	29,257,770
Ángel Cabrera	23,638,903	787,320	29,257,770
Morton Collins	22,645,216	1,781,007	29,257,770
Adel A.F. Mahmoud	22,328,083	2,098,140	29,257,770
David B. Weiner	24,020,872	405,351	29,257,770
Nancy J. Wysenski	22,310,153	2,116,070	29,257,770

Proposal 2: The ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2016.

For	Against	Abstain	Broker Non-Votes
53,244,131	260,452	179,410	0

Proposal 3: The approval of the Company's 2016 Omnibus Incentive Plan.

For	Against	Abstain	Broker Non-Votes
17,586,903	6,504,824	334,496	29,257,770

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOVIO PHARMACEUTICALS, INC.

By: /s/ Peter Kies  
Peter Kies  
Chief Financial Officer

Date: May 17, 2016